NasdaqGM:NAMSBiotechs
NewAmsterdam Pharma (NAMS) Quarterly Loss Of US$72 Million Tests Bullish Profitability Forecasts
NewAmsterdam Pharma (NasdaqGM:NAMS) has just posted its FY 2025 numbers with Q3 revenue of US$0.3 million, a basic EPS loss of US$0.61, and net income loss of US$72.0 million, setting the tone for a year that still reflects heavy investment. The company has seen quarterly revenue move between US$0.3 million and US$29.1 million over the last six reported periods, while basic EPS has ranged from a loss of US$0.15 to a loss of US$0.93. Margins remain firmly in loss-making territory even as...